title: Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form.
abstract: Ro 44-3888 is a potent and selective antagonist of GP IIb/IIIa. Following I.V. administration to rhesus monkeys, the (mean +/- SD.) clearance, volume of distribution and terminal half-life of Ro 44-3888 were 4.4 +/- 1.8 ml/min/kg, 0.8 +/- 0.4 l/kg and 2.5 +/- 0.8 h respectively. Oral administration of Ro 48-3657 (1 mg/kg), a doubly protected prodrug form, produced peak concentrations of Ro 44-3888 (152 +/- 51 ng/ml), 4.2 +/- 2.2 h after dosing. Terminal half-life and estimated bioavailability were 5.1 +/- 1.6 h and 33 +/- 6% respectively. No effect on blood pressure, heart rate or platelet counts were seen. Adenosine diphosohate (ADP) induced platelet aggregation (PA) and cutaneous bleeding times (CBT) were determined prior to and after the last of 8 daily oral administrations of Ro 48-3657 (0.25 or 0.5 mg/kg) to eight rhesus monkeys. Peak and trough plasma concentrations were proportional to dose and steady state was achieved after the second administration. Inhibition of PA and prolongation of CBT were concentration dependent. The ex vivo IC50 (82 nM) for ADP-mediated PA correlated with a value (58 nM) determined in vitro. The CBT response curve was displaced to the right of the PA curve. CBT was prolonged to > or = 25 min when levels of Ro 44-3888 exceeded 190 nM and PA was > 90% inhibited. Therefore, in rhesus monkeys, Ro 48-3657 is reproducibly absorbed and converted to its active form, is well tolerated, and has a concentration-dependent effect on PA and CBT. These properties make Ro 48-3657 an attractive candidate for evaluation in patients at high risk for arterial thrombosis.
authors.affiliation: Department of Cardiovascular Research, Genentech Inc., South San Francisco, CA 94080, USA. ken@gene.com
authors.forename: C J
authors.initials: CJ
authors.lastname: Refino
authors.forename: N B
authors.initials: NB
authors.lastname: Modi
authors.forename: S
authors.initials: S
authors.lastname: Bullens
authors.forename: C
authors.initials: C
authors.lastname: Pater
authors.forename: M T
authors.initials: MT
authors.lastname: Lipari
authors.forename: K
authors.initials: K
authors.lastname: Robarge
authors.forename: B
authors.initials: B
authors.lastname: Blackburn
authors.forename: M
authors.initials: M
authors.lastname: Beresini
authors.forename: T
authors.initials: T
authors.lastname: Weller
authors.forename: B
authors.initials: B
authors.lastname: Steiner
authors.forename: S
authors.initials: S
authors.lastname: Bunting
mesh_terms: D000284:Administration, Oral; D000578:Amidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D000818:Animals; D004334:Drug Administration Schedule; D006403:Hematologic Tests; D008253:Macaca mulatta; D010091:Oximes / Q000494:pharmacology; D010880:Piperidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011355:Prodrugs / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology
chemical_list: D000578:Amidines; D010091:Oximes; D010880:Piperidines; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011355:Prodrugs; C100916:Ro 44-3888; C100917:sibrafiban